There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Matinas BioPharma (MTNB – Research Report) and Talaris Therapeutics (TALS – Research Report) with bullish sentiments.
Matinas BioPharma (MTNB)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Matinas BioPharma, with a price target of $3.00. The company’s shares closed last Monday at $0.88.
According to TipRanks.com, Fein ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Matinas BioPharma has an analyst consensus of Moderate Buy, with a price target consensus of $3.00.
See today’s best-performing stocks on TipRanks >>
Talaris Therapeutics (TALS)
In a report released today, Ram Selvaraju from H.C. Wainwright maintained a Buy rating on Talaris Therapeutics, with a price target of $12.00. The company’s shares closed last Monday at $1.39, close to its 52-week low of $1.16.
According to TipRanks.com, Selvaraju has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Talaris Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $6.67.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MTNB:
- RECHARGE RESOURCES ENGAGES JMK EXPLORATION CONSULTING FOR GEORGIA LAKE LITHIUM PROJECT
- H.C. Wainwright Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)
- H.C. Wainwright Remains a Buy on Americas Gold and Silver (USAS)
- Vitru Announces Commencement of Rights Offering
- Insider Buy on ETNB Stock Inspiring Copycat Investors
